ZebraEye utilizes artificial intelligence to analyze ophthalmic images for the rapid detection of rare eye diseases, achieving results in under one minute. This technology addresses the high misdiagnosis rate of over 40% in rare eye conditions, significantly reducing the risk of improper treatment and potential vision loss.
Funding
$40K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Rare eye diseases are often misdiagnosed due to their complexity and the limitations of standard diagnostic methods, leading to delayed or incorrect treatment and potential vision loss. The high misdiagnosis rate, exceeding 40% in some cases, underscores the need for more accurate and efficient diagnostic tools.
Solution
ZebraEye offers an AI-powered ophthalmic image analysis system designed to assist physicians in the rapid and accurate detection of rare eye pathologies. By analyzing ophthalmic images, the system aims to reduce the risk of misdiagnosis and ensure that patients receive appropriate and timely treatment. The technology identifies rare eye pathologies within one minute, providing doctors with critical information to inform their clinical decisions and minimize the risk of vision loss due to improper treatment.
Target Audience
The primary target audience includes ophthalmologists and other eye care professionals who require advanced diagnostic tools for the detection of rare eye diseases.
Features
- AI-driven analysis of ophthalmic images for the detection of rare eye diseases.
- Rapid results, with pathology identification in under one minute.
- Web-based interface for easy access and use.
- Aims to reduce the risk of misdiagnosis and improper treatment.